Search
Now showing items 1-5 of 5
Effect of Levosimendan in Patients with Severe Systolic Heart Failure and Worsening Renal Function
(ARQUIVOS BRASILEIROS CARDIOLOGIA, 2012)
Background: Levosimendan, a calcium sensitizer, increases the sensitivity of the heart to calcium, thus increasing myocardial contractility without a rise in intracellular calcium. It was recently shown that levosimendan ...
Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure
(BMC, 2016)
Substantial attention and resources have been directed to improving outcomes of patients with critical illnesses, in particular sepsis, but all recent clinical trials testing various interventions or strategies have failed ...
Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)
(WILEY, 2017)
Organ injury and impairment are commonly observed in patients with acute heart failure (AHF), and congestion is an essential pathophysiological mechanism of impaired organ function. Congestion is the predominant clinical ...
Efficacy of levosimendan in patients with chronic heart failure: Does rhythm matter?
(AVES YAYINCILIK, 2010)
Objective: Leyosimendan is a relatively new inotropic agent. Unlike other inotropic agents, Levosimendan does not increase cellular calcium intake, so that, does not cause intracellular calcium overload and related ...
Acute Effects of Levosimendan and Dobutamine on QRS Duration in Patients with Heart Failure
(ARQUIVOS BRASILEIROS CARDIOLOGIA, 2010)
Background: Levosimendan is a novel inotropic agent that enhances cardiac contractility without increasing cellular calcium intake, so that it is not supposed to cause intracellular calcium overload and related arrhythmias. ...